Innate Pharma SA announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 and 102.
Innate Pharma SA announced that the U.S. Food and Drug Administration has placed a partial clinical hold on the lacutamab IND leading to a pause in new patient enrollment to the Company’s ongoing lacutamab trials IPH4102-201 and 102.